Pharmaceutical company makes commitments to EU antitrust chief

A South African firm commits to reduce prices significantly on three crucial European cancer drugs to avoid abuse of its dominant market position. EU's competition commissioner is satisfied with costs saved for European healthcare system gleaned from the firm's pledge.
BY LOUISE WENDT JENSEN, TRANSLATED BY NIELSINE NIELSEN & DANIEL FRANK CHRISTENSEN

BRUXELLES

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading